Clinical Trials and Translational Research Advisory Committee (CTAC)
Upcoming CTAC Meeting
The 52nd meeting of CTAC scheduled for November 8, 2023 is cancelled. The next CTAC meeting will take place on March 13th, 2024, and the agenda will be available on the CTAC meeting page approximately 10 days prior to the meeting.
CTAC is an external oversight committee that advises NCI leadership on ways to strengthen NCI's clinical and translational research enterprises, including both intramural and extramural research. CTAC is composed of leading authorities across the entire continuum of cancer research, prevention, and treatment. The committee advises NCI leadership on ways to build strong scientific infrastructures that engage a broad coalition of stakeholders involved in the clinical trials and translational research processes. CTAC is chaired by the NCI director or a designee. The CCCT director serves as the executive secretary, and CCCT staff facilitates CTAC operations.
Roles and responsibilities of CTAC include:
- Providing strategic advice and direction regarding NCI's clinical trials and translational research portfolio
- Advising NCI on policies, procedures, processes, and tools that should be developed and implemented for prioritization, management, coordination, and administration of NCI-funded clinical trials
- Providing a forum for the clinical trials and translational research communities to give advice to the NCI director
For information on CTAC's membership, charter, meeting materials, and working group reports, please visit the CTAC website.